Simplified medical abortion screening

a demonstration project

Elizabeth G. Raymond, Yi Ling Tan, Rodica Comendant, Irina Sagaidac, Stelian Hodorogea, Melissa Grant, Patricio Sanhueza, Emigdio Van Pratt, Ginger Gillespie, Christy M Boraas, Mark A. Weaver, Ingrida Platais, Manuel Bousieguez, Beverly Winikoff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The objectives were to evaluate the safety and acceptability of outpatient medical abortion in selected women without a pretreatment ultrasound or pelvic examination. Study design: We conducted a prospective case-series study to estimate the incidence of serious adverse events (death, life-threatening event, hospitalization, transfusion or any other medical problem that we judged to be significant), surgical completion of the abortion and satisfaction in women provided with medical abortion without a pretreatment ultrasound or pelvic examination. We enrolled 406 women requesting medical abortion in Moldova, Mexico and the United States. To be eligible, a woman must have been certain that her last menstrual period started within the prior 56 days, have had regular menses before the pregnancy, not have used hormonal contraceptives in the prior 2 months (in the United States and Mexico) or 3 months (in Moldova), have no risk factors for or symptoms of ectopic pregnancy, and not have had an ultrasound or pelvic exam in this pregnancy. One site also excluded women with uterine enlargement on abdominal palpation. Each participant received mifepristone (200 mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites) and was followed until complete abortion, defined as requiring no further treatment. Results: Of the 365 (90%) participants who provided sufficient follow-up information for analysis, 347 (95%) had complete abortion without additional treatment, 5 (1%) had surgical aspiration, and 10 (3%) had extra misoprostol. Three participants (1%) had serious adverse events; these included two hospital admissions for heavy bleeding managed with aspiration and one diagnosis of persistent gestational sac 19 days after enrollment. Most (317, 90%) participants were pleased with omitting the pretreatment ultrasound and pelvic exam. Conclusions: In this study, medical abortion without screening ultrasound or pelvic exam resulted in no serious adverse events that were likely to have been prevented by those tests and was highly acceptable. Implications: Screening for medical abortion without exam or ultrasound shows promise as a means for increasing access to this service. More research is needed to develop screening criteria that are more inclusive and simpler for clinical use.

Original languageEnglish (US)
Pages (from-to)292-296
Number of pages5
JournalContraception
Volume97
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Gynecological Examination
Moldova
Misoprostol
Mexico
Gestational Sac
Mifepristone
Pregnancy
Menstruation
Ectopic Pregnancy
Palpation
Contraceptive Agents
Hospitalization
Outpatients
Hemorrhage
Safety
Incidence
Therapeutics
Research

Keywords

  • Ectopic pregnancy
  • Last menstrual period
  • Medical abortion
  • Ultrasound

PubMed: MeSH publication types

  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

Cite this

Raymond, E. G., Tan, Y. L., Comendant, R., Sagaidac, I., Hodorogea, S., Grant, M., ... Winikoff, B. (2018). Simplified medical abortion screening: a demonstration project. Contraception, 97(4), 292-296. https://doi.org/10.1016/j.contraception.2017.11.005

Simplified medical abortion screening : a demonstration project. / Raymond, Elizabeth G.; Tan, Yi Ling; Comendant, Rodica; Sagaidac, Irina; Hodorogea, Stelian; Grant, Melissa; Sanhueza, Patricio; Van Pratt, Emigdio; Gillespie, Ginger; Boraas, Christy M; Weaver, Mark A.; Platais, Ingrida; Bousieguez, Manuel; Winikoff, Beverly.

In: Contraception, Vol. 97, No. 4, 01.04.2018, p. 292-296.

Research output: Contribution to journalArticle

Raymond, EG, Tan, YL, Comendant, R, Sagaidac, I, Hodorogea, S, Grant, M, Sanhueza, P, Van Pratt, E, Gillespie, G, Boraas, CM, Weaver, MA, Platais, I, Bousieguez, M & Winikoff, B 2018, 'Simplified medical abortion screening: a demonstration project', Contraception, vol. 97, no. 4, pp. 292-296. https://doi.org/10.1016/j.contraception.2017.11.005
Raymond EG, Tan YL, Comendant R, Sagaidac I, Hodorogea S, Grant M et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018 Apr 1;97(4):292-296. https://doi.org/10.1016/j.contraception.2017.11.005
Raymond, Elizabeth G. ; Tan, Yi Ling ; Comendant, Rodica ; Sagaidac, Irina ; Hodorogea, Stelian ; Grant, Melissa ; Sanhueza, Patricio ; Van Pratt, Emigdio ; Gillespie, Ginger ; Boraas, Christy M ; Weaver, Mark A. ; Platais, Ingrida ; Bousieguez, Manuel ; Winikoff, Beverly. / Simplified medical abortion screening : a demonstration project. In: Contraception. 2018 ; Vol. 97, No. 4. pp. 292-296.
@article{6da202f1c4ba4cefa4bffbdb4670ef5c,
title = "Simplified medical abortion screening: a demonstration project",
abstract = "Objectives: The objectives were to evaluate the safety and acceptability of outpatient medical abortion in selected women without a pretreatment ultrasound or pelvic examination. Study design: We conducted a prospective case-series study to estimate the incidence of serious adverse events (death, life-threatening event, hospitalization, transfusion or any other medical problem that we judged to be significant), surgical completion of the abortion and satisfaction in women provided with medical abortion without a pretreatment ultrasound or pelvic examination. We enrolled 406 women requesting medical abortion in Moldova, Mexico and the United States. To be eligible, a woman must have been certain that her last menstrual period started within the prior 56 days, have had regular menses before the pregnancy, not have used hormonal contraceptives in the prior 2 months (in the United States and Mexico) or 3 months (in Moldova), have no risk factors for or symptoms of ectopic pregnancy, and not have had an ultrasound or pelvic exam in this pregnancy. One site also excluded women with uterine enlargement on abdominal palpation. Each participant received mifepristone (200 mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites) and was followed until complete abortion, defined as requiring no further treatment. Results: Of the 365 (90{\%}) participants who provided sufficient follow-up information for analysis, 347 (95{\%}) had complete abortion without additional treatment, 5 (1{\%}) had surgical aspiration, and 10 (3{\%}) had extra misoprostol. Three participants (1{\%}) had serious adverse events; these included two hospital admissions for heavy bleeding managed with aspiration and one diagnosis of persistent gestational sac 19 days after enrollment. Most (317, 90{\%}) participants were pleased with omitting the pretreatment ultrasound and pelvic exam. Conclusions: In this study, medical abortion without screening ultrasound or pelvic exam resulted in no serious adverse events that were likely to have been prevented by those tests and was highly acceptable. Implications: Screening for medical abortion without exam or ultrasound shows promise as a means for increasing access to this service. More research is needed to develop screening criteria that are more inclusive and simpler for clinical use.",
keywords = "Ectopic pregnancy, Last menstrual period, Medical abortion, Ultrasound",
author = "Raymond, {Elizabeth G.} and Tan, {Yi Ling} and Rodica Comendant and Irina Sagaidac and Stelian Hodorogea and Melissa Grant and Patricio Sanhueza and {Van Pratt}, Emigdio and Ginger Gillespie and Boraas, {Christy M} and Weaver, {Mark A.} and Ingrida Platais and Manuel Bousieguez and Beverly Winikoff",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.contraception.2017.11.005",
language = "English (US)",
volume = "97",
pages = "292--296",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Simplified medical abortion screening

T2 - a demonstration project

AU - Raymond, Elizabeth G.

AU - Tan, Yi Ling

AU - Comendant, Rodica

AU - Sagaidac, Irina

AU - Hodorogea, Stelian

AU - Grant, Melissa

AU - Sanhueza, Patricio

AU - Van Pratt, Emigdio

AU - Gillespie, Ginger

AU - Boraas, Christy M

AU - Weaver, Mark A.

AU - Platais, Ingrida

AU - Bousieguez, Manuel

AU - Winikoff, Beverly

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Objectives: The objectives were to evaluate the safety and acceptability of outpatient medical abortion in selected women without a pretreatment ultrasound or pelvic examination. Study design: We conducted a prospective case-series study to estimate the incidence of serious adverse events (death, life-threatening event, hospitalization, transfusion or any other medical problem that we judged to be significant), surgical completion of the abortion and satisfaction in women provided with medical abortion without a pretreatment ultrasound or pelvic examination. We enrolled 406 women requesting medical abortion in Moldova, Mexico and the United States. To be eligible, a woman must have been certain that her last menstrual period started within the prior 56 days, have had regular menses before the pregnancy, not have used hormonal contraceptives in the prior 2 months (in the United States and Mexico) or 3 months (in Moldova), have no risk factors for or symptoms of ectopic pregnancy, and not have had an ultrasound or pelvic exam in this pregnancy. One site also excluded women with uterine enlargement on abdominal palpation. Each participant received mifepristone (200 mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites) and was followed until complete abortion, defined as requiring no further treatment. Results: Of the 365 (90%) participants who provided sufficient follow-up information for analysis, 347 (95%) had complete abortion without additional treatment, 5 (1%) had surgical aspiration, and 10 (3%) had extra misoprostol. Three participants (1%) had serious adverse events; these included two hospital admissions for heavy bleeding managed with aspiration and one diagnosis of persistent gestational sac 19 days after enrollment. Most (317, 90%) participants were pleased with omitting the pretreatment ultrasound and pelvic exam. Conclusions: In this study, medical abortion without screening ultrasound or pelvic exam resulted in no serious adverse events that were likely to have been prevented by those tests and was highly acceptable. Implications: Screening for medical abortion without exam or ultrasound shows promise as a means for increasing access to this service. More research is needed to develop screening criteria that are more inclusive and simpler for clinical use.

AB - Objectives: The objectives were to evaluate the safety and acceptability of outpatient medical abortion in selected women without a pretreatment ultrasound or pelvic examination. Study design: We conducted a prospective case-series study to estimate the incidence of serious adverse events (death, life-threatening event, hospitalization, transfusion or any other medical problem that we judged to be significant), surgical completion of the abortion and satisfaction in women provided with medical abortion without a pretreatment ultrasound or pelvic examination. We enrolled 406 women requesting medical abortion in Moldova, Mexico and the United States. To be eligible, a woman must have been certain that her last menstrual period started within the prior 56 days, have had regular menses before the pregnancy, not have used hormonal contraceptives in the prior 2 months (in the United States and Mexico) or 3 months (in Moldova), have no risk factors for or symptoms of ectopic pregnancy, and not have had an ultrasound or pelvic exam in this pregnancy. One site also excluded women with uterine enlargement on abdominal palpation. Each participant received mifepristone (200 mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites) and was followed until complete abortion, defined as requiring no further treatment. Results: Of the 365 (90%) participants who provided sufficient follow-up information for analysis, 347 (95%) had complete abortion without additional treatment, 5 (1%) had surgical aspiration, and 10 (3%) had extra misoprostol. Three participants (1%) had serious adverse events; these included two hospital admissions for heavy bleeding managed with aspiration and one diagnosis of persistent gestational sac 19 days after enrollment. Most (317, 90%) participants were pleased with omitting the pretreatment ultrasound and pelvic exam. Conclusions: In this study, medical abortion without screening ultrasound or pelvic exam resulted in no serious adverse events that were likely to have been prevented by those tests and was highly acceptable. Implications: Screening for medical abortion without exam or ultrasound shows promise as a means for increasing access to this service. More research is needed to develop screening criteria that are more inclusive and simpler for clinical use.

KW - Ectopic pregnancy

KW - Last menstrual period

KW - Medical abortion

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85039455124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039455124&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2017.11.005

DO - 10.1016/j.contraception.2017.11.005

M3 - Article

VL - 97

SP - 292

EP - 296

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -